Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
16.48
-0.74 (-4.30%)
At close: Nov 20, 2026, 4:00 PM EST
16.50
+0.02 (0.12%)
After-hours: Nov 20, 2026, 7:31 PM EST
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
According to 21 analysts polled by S&P Global, Ultragenyx Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $24.8. The average 1-year stock price forecast is 50.49% higher than the current stock price, while the lowest is $16 (-2.91%) and the highest is $39 (+136.65%).
Price Target: $24.8 (+50.49%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 13 | 8 | 8 | 8 |
| Buy | 5 | 5 | 5 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 10 | 11 | 11 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 20 | 20 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Buy Reiterates $35 → $24 | Buy | Reiterates | $35 → $24 | +45.63% | Nov 17, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $22 | Hold | Maintains | $22 | +33.50% | Nov 16, 2026 |
| Citi | Citi | Buy Maintains $32 → $22 | Buy | Maintains | $32 → $22 | +33.50% | Nov 5, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $33 | Buy | Reiterates | $33 | +100.24% | Nov 5, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $36 | Buy | Maintains | $36 | +118.45% | Nov 5, 2026 |
Financial Forecast
Revenue This Year
766.11M
from 673.00M
Increased by 13.83%
Revenue Next Year
969.30M
from 766.11M
Increased by 26.52%
EPS This Year
-3.05
from -5.83
EPS Next Year
1.43
from -3.05
EPS and Forward PE are based on non-GAAP adjusted numbers.